

Dear editor,

Thank you very much for the editorial staff and reviewer's hard-work in processing our manuscript. We have carefully read the comments made by the editor and the reviewer. The comments are addressed below in a point-by-point manner.

Reviewer #1:

Specific Comments to Authors:

1) Part The main symptom of Nilotinib "A spontaneous decrease.... what does it mean? not clear and should be clarified.

A: Revised:"The spontaneous decrease of bilirubin levels can be obtained without medication or phototherapy treatment".

2) Part Nilotinib induced hyperbilirubinemia" It's very disorganized. The authors should clarify their hypothesis in an understandable manner. And should be well organised.

A: We have supplemented and modified this part.

3) Part Conclusion,... unclear enough. Difficult to understand the conclusion . should be clarified and a bit shortened.

A: We have rewritten.

4) Page 5, In another case report.... What about the other case reports? what did the authors mean is very confusing.

A: We revised: In a case reported by Cortes JE et al.

5) Page 7 Here we report a case What does it mean? When did they report the case? Or do they want to cite an another article? should be clarified.

A: Yes, the case report we just published is quoted here

6) The whole manuscript should be re-evaluated by an experienced author experienced in medical writing

A: Thank you for your suggestion. We have invited hematology experts to review it again

Reviewer #2:

Specific Comments to Authors: This report is nicely presented and possesses a clinical value, so I recommend publication after dealing with the following issues, - Please double-check the English language. -Please add one more section about tyrosine kinase inhibitors and their generations in detail. -It should be nice if you can discuss the current approaches used for minimizing nilotinib cytotoxicity. - Please add a conclusion and

recommendations.

A: Thank you for your recommendation. The language of our article has been polished by native language experts. The conclusion part is added at the end of the article, and suggestions on the use of nilotinib for liver damage are put forward.